Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - enzalutamide, quantity: 40 mg - capsule, soft - excipient ingredients: gelatin; purified water; caprylocaproyl macrogolglycerides; butylated hydroxyanisole; butylated hydroxytoluene; titanium dioxide; sorbitol; glycerol; propylene glycol; ethyl acetate; ethanol; isopropyl alcohol; strong ammonia solution; iron oxide black; macrogol 400; polyvinyl acetate phthalate - xtandi is indicated for:,? the treatment of patients with metastatic hormone-sensitive prostate cancer.,? the treatment of patients with non-metastatic castration-resistant prostate cancer (see prosper, section 5.1 clinical trials).,? the treatment of patients with metastatic castration resistant prostate cancer following failure of androgen deprivation therapy in whom chemotherapy is not yet indicated.,? the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

United States - English - NLM (National Library of Medicine)

astellas pharma us, inc. - ceftizoxime sodium (unii: 26337d5x88) (ceftizoxime - unii:c43c467dpe) - solution - 1 g in 50 ml - cefizox (ceftizoxime injection) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. lower respiratory tract infections caused by klebsiella spp.; proteus mirabilis ; escherichia coli; haemophilus influenzae including ampicillin­resistant strains; staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); serratia spp.; enterobacter spp.; bacteroides spp.; and streptococcus spp. including s. pneumoniae , but excluding enterococci. urinary tract infections caused by staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); escherichia coli ; pseudomonas spp. including p. aeruginosa ; proteus mirabilis ; p. vulgaris ; providencia rettgeri (formerly proteus rettgeri ) and morganella morganii (formerly proteus morganii ); klebsiella spp.; serratia spp. including s. marcescens ; and enterobacter spp. gonorrhea including uncomplicated cervical and urethral gonorrhea caused by neisseria gonorrhoeae . pelvic inflammatory dise

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: colloidal anhydrous silica; macrogol 8000; macrogol 7000000; hypromellose; butylated hydroxytoluene; iron oxide yellow; magnesium stearate - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - micafungin sodium, quantity: 101.73 mg (equivalent: micafungin, qty 100 mg) - injection, powder for - excipient ingredients: citric acid; sodium hydroxide; lactose monohydrate - mycamine is indicated for: ? treatment of invasive candidiasis in children and adults ? treatment of oesophageal candidiasis in adults, adolescents greater than or equal to 16 years of age and the elderly patients for whom intravenous therapy is appropriate ? prophylaxis of candida infection in children and adult patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/?l) for 10 or more days.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - micafungin sodium, quantity: 50.86 mg (equivalent: micafungin, qty 50 mg) - injection, powder for - excipient ingredients: citric acid; sodium hydroxide; lactose monohydrate - mycamine is indicated for: ? treatment of invasive candidiasis in children and adults ? treatment of oesophageal candidiasis in adults, adolescents greater than or equal to 16 years of age and the elderly patients for whom intravenous therapy is appropriate ? prophylaxis of candida infection in children and adult patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/?l) for 10 or more days.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus - oral capsule - 1mg

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 0.5 mg - capsule, hard - excipient ingredients: lactose monohydrate; croscarmellose sodium; purified water; iron oxide yellow; magnesium stearate; hypromellose; titanium dioxide; gelatin; hyprolose; butan-1-ol; iron oxide red; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: peg-60 hydrogenated castor oil; ethanol - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 5 mg - capsule, hard - excipient ingredients: lactose monohydrate; hypromellose; iron oxide red; gelatin; magnesium stearate; titanium dioxide; croscarmellose sodium; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 1 mg - capsule, hard - excipient ingredients: titanium dioxide; croscarmellose sodium; hypromellose; magnesium stearate; lactose monohydrate; gelatin; purified water; hyprolose; butan-1-ol; iron oxide red; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.